For a small company, Ligand Pharmaceuticals ( LGND) has been making a lot of news lately, much of which hasn't been encouraging. Delisted by Nasdaq and investigated by the Securities and Exchange Commission, the San Diego-based company has experienced a number of financial and regulatory disappointments in recent months. The company's travails have prompted its largest shareholder, investment management firm Third Point, to say it will line up eight candidates to challenge Ligand's nominees for the board. The showdown is scheduled for the annual meeting Jan. 31. Third Point owns just under 10% of Ligand's stock. Ligand cleared up some longtime, nagging issues when it announced Nov. 18 the filing of its 10-K report with the SEC for the 2004 fiscal year. The report contains restated financial results for 2003 and 2002, as well as restatements of selected data for 2001 and 2000. The formal SEC investigation of the restatements continues, and Ligand says it's cooperating. In addition, the company's independent auditor issued an adverse report on the effectiveness of its internal controls during 2004. Ligand says it's implementing corrective measures. Ligand also recently issued preliminary revenue estimates for the third quarter that ended Sept. 30, as well as preliminary results for the first and second quarters of 2005. For the first half of 2005, it lost $25.6 million, or 35 cents a share, on revenue of $76.8 million. For the same period last year, it lost $44 million, or 60 cents a share, on revenue of $54.2 million.
When asked by one analyst during a Nov. 18 conference call if the whole company might be sold, David Robinson, the chairman and CEO, said Ligand is "open to all strategic opportunities to enhance our shareholders value." The best way to improve shareholder value is to replace the board, says Daniel S. Loeb, chief executive of Third Point in a letter to shareholders. Third Point issued its challenge just before Ligand announced its own plan to seek alternatives. Loeb says he acted because the company ignored his previous request to add three Third Point nominees to the board to help devise a new strategy. Meanwhile, Ligand's stock has held up well since it hit a 52-week low of $4.75 in April. It closed Wednesday at $10.40, but prices have bounced between about $4 and $24 during the past three years. Ligand's revenue comes from a mixture of marketed products and experimental compounds for which it receives royalties and milestone payments through deals with companies including Pfizer ( PFE), Eli Lilly ( LLY), Wyeth ( WYE) and GlaxoSmithKline ( GSK). Some of those deals have hit a wall either in the lab or at the Food and Drug Administration. In September,
the FDA rejected an application from Pfizer for the osteoporosis treatment Oporia. Ligand would get milestone payments if the drug is approved, as well as additional royalties on worldwide sales. Pfizer said it will discuss its application with the agency and consider various possibilities. Ligand's Robinson told investors on Nov. 18 that while he was disappointed with the FDA's decision, he expects Oporia to be "an important asset going forward." Pfizer also submitted Oporia for FDA review as a treatment for vaginal atrophy. Pfizer declined to comment on the status of this application. Pfizer continues to work on a version of Oporia for breast cancer.
Ligand and Wyeth are in late-stage clinical trials on an experimental drug for osteoporosis, and Robinson said he expected Wyeth to submit an application to the FDA. Wyeth has stopped trying to develop a related compound as a cancer treatment. Two experimental contraceptives being developed with Wyeth have been put on hold. Other compounds using Ligand technology that are in mid-stage clinical testing include treatments for diabetes and clogged arteries being developed by Eli Lilly. Research on another diabetes drug has been set aside for now. In addition, GlaxoSmithKline is in mid-stage clinical trials on compounds for heart disease and insufficient blood platelets.